Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2012 | 02:00pm CEST

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
Zogenix
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news
Date Title
12:28p US CONCRETE : U.S. Concrete reports 1Q loss
12:28p Northrop Grumman Announces Winners of UK's CyberCenturion Competition to Find Cyber Security Talent of the Future
12:27p EXTRA : BT To Step Up Broadband And 4G Roll-Out While Raising Dividend
12:26p MCEWEN MINING INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
12:26p INNOSPEC INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
12:26p MANULIFE FINANCIAL : Canada's Manulife posts 45 percent rise in profit
12:25p XLMEDIA : Form 8.3 - XLMedia Plc
12:25p ULTIMATE SOFTWARE : “People First” in Action
12:25p CSM BAKERY SOLUTIONS : Voluntarily Recalls 8" Single Layer Red Velvet Cake Sold at Safeway and 12” Decorated Chocolate Chip Cookie Sold at Acme and Jewel Stores Due to Undeclared Peanut Allergen
12:25p CIRCLE OIL : TR 1 Notification of Major Interest in Shares
Latest news
Advertisement
Hot News 
BANGO : Implements Google Play Direct Carrier Billing In India
FILTRONIC : New Contract Win
FALANX GROUP LIMITED : Acquisition, Placing and issue of Loan Notes
DELTEX MEDICAL : 4 May 2016 Enhanced performance TruFlow probe launched in UK
EMPRESARIA : Makes Good Start To 2016 With Net Fee Income Higher
Most Read News
05/04DJAustralia March Trade Deficit Narrows
05/04DJAustralian March Retail Sales Rise
05/04 KANTAR HEALTH : Names Diana Tan General Manager for China, Expanding Expertise in Innovative Patient Insights
05/04 PRODUCER PRICE SURVEY : March 2016
12:10a AUSTRADE AUSTRALIAN TRADE COMMISSION : Outcomes from LNG 18
Most recommended articles
05/03DJUBS Shares Drop As Profit Slumps
06:26a MANULIFE FINANCIAL : Canada's Manulife posts 45 percent rise in profit
06:23a TIME : revenue rises slightly
06:18a TELUS : Canada's Telus to divest stake in unit
06:15aDJIndonesia and Neighbors to Patrol Seas as Kidnappings Surge